Hemogenyx Pharmaceuticals Plc (LON:HEMO – Get Free Report) traded up 1.1% during trading on Thursday . The stock traded as high as GBX 589.94 and last traded at GBX 530. Approximately 7,194 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 22,654 shares. The stock had previously closed at GBX 524.
Hemogenyx Pharmaceuticals Stock Performance
The company has a market cap of £35.36 million, a P/E ratio of -3.05 and a beta of 1.50. The business’s 50 day simple moving average is GBX 674.81 and its 200 day simple moving average is GBX 800.16. The company has a current ratio of 1.38, a quick ratio of 6.72 and a debt-to-equity ratio of 167.66.
About Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.
See Also
- Five stocks we like better than Hemogenyx Pharmaceuticals
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
- Merchants Bancorp’s Rally Is Testing How Much Risk Investors Will Overlook
- Lululemon’s Earnings Beat Hid a Bigger Problem for Its Turnaround Story
- MarketBeat Week in Review – 08/31 – 09/04
Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
